Common Stock, par value $0.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
BIAFNASDAQEQUITYCurrent
Item 8.01. Other Events. On November 19, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) released a newsletter providing an overview of certain recent developments. A copy of the newsletter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
bioAffinity Technologies, Inc. · 8-K · Filed 2026-11-19
Exhibit 99.1 bioAffinity Technologies newsletter, 2nd Edition, Fall/Winter 2026 Company Newsletter 2nd Edition Fall/Winter 2026 Nasdaq: BIAF Message from our CEO We look forward to an exciting and productive holiday season at bioAffinity Technologies as we continue to expand the reach and potential of our innovative technologies. CyPath Lung continues to gain commercial momentum, with growing adoption by physicians and strong year-over-year growth in test volume. At the same time, we are opening important new opportunities to bring CyPath Lung to more patients, including our nationwide federal healthcare distribution agreement with AvMEDICAL and our expanding engagement with physicians, administrators and leaders serving our nation’s veterans. We are also advancing the science behind CyPath Lung, including its potential use in the surveillance of lung cancer survivors, and developing precision diagnostics to characterize lung inflammation in patients with asthma and COPD that may enable physicians to make more informed treatment choices for individual patients. We also see promising results of our research to advance our therapeutic discoveries using self-d…
Open exhibit ↗